Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The United Laboratories International Holdings ( (HK:3933) ) has issued an update.
The United Laboratories International Holdings Limited announced the FDA approval of its investigational new drug application for UBT37034 Injection, a Class 1 innovative drug targeting overweight and obesity. This approval marks a significant step for the company in enhancing its competitiveness and creativity within the biopharmaceutical industry, potentially benefiting its operations and stakeholders.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited operates in the biopharmaceutical industry, focusing on the development of innovative drugs. Its primary products include peptide receptor agonists, with a market focus on addressing conditions such as overweight and obesity.
Average Trading Volume: 12,155,004
Technical Sentiment Signal: Buy
Current Market Cap: HK$27.33B
For an in-depth examination of 3933 stock, go to TipRanks’ Overview page.